Adaptimmune Therapeutics PLCAdaptimmune Therapeutics PLC - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This SDG score for Adaptimmune Therapeutics PLC represents its transparency towards the United Nations Sustainable Development Goals. If you work at Adaptimmune Therapeutics PLC and you wish to licence your ESG rating, please contact us. Alternative companies in the rating industry group for Adaptimmune Therapeutics PLC are displayed.

Adaptimmune Therapeutics PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 4.8, social score of 3.2 and governance score of 5.3.

SDG Transparency Score for Adaptimmune Therapeutics PLC 
Low
0 - 3

4.7

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Adaptimmune Therapeutics PLC 
4.8

Environmental

3.2

Social

5.3

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
1121Protagonist Therapeutics Inc
4.8
High
1121Shanghai Medicilon Inc
4.8
High
1156Adaptimmune Therapeutics PLC
4.7
High
1156Albireo Pharma Inc
4.7
High
1156Arcticzymes Technologies ASA
4.7
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Adaptimmune Therapeutics PLC have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC report the average age of the workforce?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose cybersecurity risks?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC offer flexible work?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC conduct supply chain audits?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose water use targets?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Adaptimmune Therapeutics PLC have a product recall in the last two years?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose incidents of discrimination?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Adaptimmune Therapeutics PLC issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose parental leave metrics?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Adaptimmune Therapeutics PLC involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose its waste policy?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC report according to TCFD requirements?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose energy use targets?

LockedSign up for free to unlock

Does Adaptimmune Therapeutics PLC disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Adaptimmune Therapeutics PLC have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Adaptimmune Therapeutics PLC
These potential risks are based on the size, segment and geographies of the company.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Sorry!

Failed to process!